ClinicalTrials.gg
RecruitingNCT04573673NEUROSTIM-SEP1Updated Dec 23, 2025

Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis.

An interventional study of PTNS de verum and PTNS placebo in Multiple Sclerosis and Lower Urinary Tract Symptoms, sponsored by University Hospital, Lille. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by University Hospital, Lille · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Multiple Sclerosis by University Hospital, Lille — 4 open to participants now, 4 under way, none of them phase 3. Multiple Sclerosis · University Hospital, Lille.

Started
2021
the only one that year
No phase
4 of 11
3 open now
Registered
8th of 11
by date

Among the 11 studies in Multiple Sclerosis by University Hospital, Lille, this one is the only one that started in 2021, is one of 4 with no phase, and was the 8th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

4 of the 11 studies in Multiple Sclerosis by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Multiple Sclerosis by University Hospital, Lille, or all of them as a file.
02

Study summary

The present trial is designed to assess the efficacy and safety of transcutaneous tibial neuro-stimulation (TTNS) in improving bladder emptying in multiple sclerosis (MS) patients.

Patients presenting with MS and performing clean intermittent self-catheterization (CISC) to empty the bladder in the context of voiding dysfunction, will be eligible.

Included patients will be randomly assigned to two distinct arms

  • PTNS de verum : patients will be treated with transcutaneous tibial neuro-stimulation at a rate of one session of 30 consecutive minutes daily for a period of 12 weeks.
  • PTNS placebo : Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for a period of 12 weeks (same treatment regimen as the experimental group).

Efficacy in improving voiding dysfunction will be assessed 12 weeks after randomization using the BVE ratio (Bladder Voiding Efficiency) = Ratio of urine volume / total bladder volume.

03

Conditions studied

  • Multiple Sclerosis
  • Lower Urinary Tract Symptoms

Keywords

  • Multiple sclerosis
  • Voiding dysfunction
  • Bladder-sphincter dyssinergia
  • Tibial neuro-stimulation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with a diagnosis of multiple sclerosis
  • Patient with bladder-sphincter dyssinergia
  • Patient using clean intermittent self-catheterization as exclusive bladder management
  • Patient who has given written consent
  • Socially insured patient
  • Patient willing to comply with all study procedures and study duration

Exclusion criteria

Exclusion Criteria:

  • Patient with other associated neurological pathology
  • Patient with an Expanded Disability Status Scale (EDSS) score ≥ 6
  • Patient with recurrent urinary tract infections (> 3 episodes / year)
  • Patient with uncontrolled overactive bladder
  • Patient with uncontrolled detrusor hyperactivity
  • Patient with a bladder compliance disorder
  • Patient with tibial neuro-stimulation in the last 3 months
  • Patient treated with a sacral neuro-modulation
  • Patient who has received an intradermal injection of botulinum toxin A within the last 9 -months Patient who received alpha-blocker treatment within the last month Patient with benign prostatic hypertrophy (prostate volume > 40 cc) - Last ultrasound scan \< 6 months.

Patient with one or more bladder diverticulum(s) Patient with unilateral or bilateral renal Patient with unilateral or bilateral vesico-ureteral reflux Patient with impaired renal function ( according to CKD-EPI \< 60 ml/min/1.73m2) Patient with a metallic prosthesis on the lower limb Patient with a Pacemaker Pregnant patient

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    PTNS verum

    Patients will be treated with transcutaneous tibial neuro-stimulation with one 30-minute session daily for a period of 12 weeks.

    Device: PTNS de verum

  • Sham comparator
    PTNS placebo

    Patients will be treated with placebo (i.e. no current) transcutaneous tibial neuro-stimulation for 30 consecutive minutes daily for 12 weeks (same treatment regimen as the experimental group).

    Device: PTNS placebo

Interventions

  • DevicePTNS de verum

    The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. The amplitude (Volt) will be adjusted by the patient according to the feeling.

    Also known as: Peristim Pro (CEFAR-COMPEX®)

  • DevicePTNS placebo

    The device will be set to program P-4: Frequency 20Htz, Pulse duration = 200 µs. A resistor will be incorporated in the device to block the passage of electric current

    Also known as: Peristim Pro (CEFAR-COMPEX®

06

What researchers measure

Primary outcomes

  1. BVE ratio (Bladder Voiding Efficiency) = Ratio of urine volume / total bladder volume

    BVE will be measured during the multi-channel urodynamic study

    Time frame: At 12 weeks after randomization

Secondary outcomes

  1. Maximal flow rate (mL/s) on multi-channel urodynamic study

    Maximal flow rate will be measured during the multi-channel urodynamic study

    Time frame: At baseline, At 12 weeks after randomization

  2. Post-void residual volume (mL) on multi-channel urodynamic study

    Post-void residual volume will be measured during the multi-channel urodynamic study

    Time frame: At 12 weeks after randomization

  3. Maximal detrusor pressure during micturition (cmH2O) on multi-channel urodynamic study

    Maximal detrusor pressure during micturition will be measured during the multi-channel urodynamic study

    Time frame: At 12 weeks after randomization

  4. Mean voided volume (mL) on a three-day ambulatory measure

    Mean voided volume will be measured using an ambulatory flowmeter (Homeflow®) during three consecutive days

    Time frame: At 12 weeks after randomization

  5. Mean maximal flow rate (mL/s) on a three-day ambulatory measure

    Mean maximal flow rate will be measured using an ambulatory flowmeter (Homeflow®) during three consecutive days

    Time frame: At 12 weeks after randomization

  6. Mean post-void residual volume (mL) on a three-day ambulatory measure

    Mean post-void residual volume will be measured using an ambulatory flowmeter (Homeflow®) during three consecutive days.

    Time frame: At 12 weeks after randomization

  7. Frequency of patients who were able to stop clean intermittent self-catheterization (PVR < 100 mL)

    Mean post-void residual volume will be measured using an ambulatory flowmeter (Homeflow®) during three consecutive days

    Time frame: At 12 weeks after randomization

  8. Urinary symptoms self-reported questionnaire (USP)

    USP : Urinary Symptom Profile

    Time frame: At 12 weeks after randomization

  9. Quality of life self-reported questionnaire (Qualiveen)

    Qualiveen

    Time frame: At 12 weeks after randomization

  10. Difficulty to perform CISC self-reported questionnaire (ICDQ)

    ICDQ : Intermittent Catheterization Difficulty Questionnaire

    Time frame: At 12 weeks after randomization

  11. Digestive symptoms self-reported questionnaire (NBD)

    NBD : Neurogenic Bowel Dysfunction

    Time frame: At 12 weeks after randomization

  12. Digestive symptoms self-reported questionnaire (Wexner)

    Wexner questionnaire

    Time frame: At 12 weeks after randomization

  13. Sexual symptoms self-reported questionnaire (FSFI)

    FSFI (female) : Female Sexual Function Index

    Time frame: At 12 weeks after randomization

  14. Sexual symptoms self-reported questionnaire ( MSHQ)

    MSHQ (male) : Male Sexual Health Questionnaire

    Time frame: At 12 weeks after randomization

  15. Frequency of patients with detrusor overactivity on multi-channel urodynamic study

    Detrusor overactivity will be objectify during the multi-channel urodynamic study

    Time frame: At 12 weeks after randomization

  16. Filling volume (mL) at first detrusor unhibited contraction on multi-channel urodynamic study - If detrusor overactivity.

    Filling volume at first detrusor unhibited contraction will be measured during the multi-channel urodynamic study.

    Time frame: At 12 weeks after randomization

  17. Maximal detrusor pressure (cmH2O) on multi-channel urodynamic study - If detrusor overactivity.

    Maximal detrusor pressure will be measured during the multi-channel urodynamic study

    Time frame: At 12 weeks after randomization

  18. Maximal cystomanometric capacity (cmH2O) on multi-channel urodynamic study

    Maximal cystomanometric capacity will be measured during the multi-channel urodynamic study

    Time frame: At 12 weeks after randomization

  19. Frequency of adverse events occurring during the 12-week follow-up

    Adverse events will be exhaustively listed

    Time frame: Measured 12 weeks after randomization

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jun 2026, 54 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 54 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2020
First posted
Oct 5, 2020
StartActual
Dec 1, 2021
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04573673
Responsible party
Sponsor
First posted
Oct 5, 2020
Start date
Dec 1, 2021
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Dec 23, 2025

Study contacts

Xavier Biardeau, MD
Contact
xavier.biardeau@chru-lille.fr
03.20.44.41.73 ext. +33
Xavier Biardeau, MD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion